Steven H. Stein, M.D., is a distinguished medical professional who currently holds the position of Executive Vice President and Chief Medical Officer at Incyte Corporation, a global biopharmaceutical company focused on developing and commercializing innovative therapies. Dr. Stein joined Incyte in 2015 and has been instrumental in guiding the company's clinical development strategy and advancing its pipeline of novel therapeutics. With over two decades of experience in the pharmaceutical industry, Dr. Stein has a proven track record of leading successful drug development programs across various therapeutic areas, including oncology, hematology, and inflammation. Prior to joining Incyte, Dr. Stein held several leadership positions at major pharmaceutical companies. He served as Senior Vice President and Worldwide Head of Oncology at Pfizer, where he oversaw the development of multiple oncology drugs, including the blockbuster breast cancer treatment IBRANCE (palbociclib). Before his tenure at Pfizer, Dr. Stein worked at Merck, where he played a key role in the development of the cancer immunotherapy KEYTRUDA (pembrolizumab). Dr. Stein's extensive experience in clinical development, coupled with his deep understanding of the scientific and regulatory landscape, has been invaluable in driving Incyte's mission to improve the lives of patients with serious diseases. As Chief Medical Officer at Incyte, Dr. Stein is responsible for overseeing the company's global clinical development, medical affairs, and pharmacovigilance functions. He leads a team of dedicated professionals working to advance Incyte's diverse portfolio of investigational therapies, which includes treatments for cancer, autoimmune disorders, and other serious conditions. Under Dr. Stein's leadership, Incyte has made significant progress in bringing innovative medicines to patients, including the approval of several novel therapies, such as JAKAFI (ruxolitinib) for the treatment of myelofibrosis and polycythemia vera, and PEMAZYRE (pemigatinib) for the treatment of cholangiocarcinoma. Dr. Stein's strategic vision and commitment to scientific excellence continue to drive Incyte's growth and success in delivering life-changing therapies to patients worldwide.